Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies
- PMID: 16482476
- DOI: 10.1007/s00401-005-0027-7
Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies
Abstract
Alpha-synuclein is a major constituent of Lewy bodies, the fibrillar aggregates that form within neurons in Parkinson's disease and dementia with Lewy bodies (DLB). Recent biochemical data show that alpha-synuclein accumulates in Parkinson's disease in a detergent insoluble form. We now examine the relationship between detergent insoluble alpha-synuclein and the presence of Lewy bodies, clinical measures of dementia and biochemical parameters in a series of individuals with DLB. We found that Triton X-100 insoluble alpha-synuclein enriched nearly twofold in the temporal cortex of patients with DLB compared to age-matched controls. By contrast the total amount of alpha-synuclein protein was unchanged. Surprisingly, the degree of Triton X-100 insoluble alpha-synuclein did not correlate with either the duration of illness or the number of Lewy bodies counted using stereological methods from an adjacent block of tissue. However, the Triton X-100 soluble fraction of alpha-synuclein did correlate strongly with the expression of several heat shock proteins (HSPs) in DLB but not control cases, suggesting a coordinated HSP response in DLB neocortex.
Similar articles
-
Early alpha-synuclein lipoxidation in neocortex in Lewy body diseases.Neurobiol Aging. 2008 Mar;29(3):408-17. doi: 10.1016/j.neurobiolaging.2006.10.022. Epub 2006 Dec 12. Neurobiol Aging. 2008. PMID: 17166629
-
Accumulation of insoluble alpha-synuclein in dementia with Lewy bodies.Neurobiol Dis. 2000 Jun;7(3):192-200. doi: 10.1006/nbdi.2000.0286. Neurobiol Dis. 2000. PMID: 10860784
-
Relationship of phosphorylated alpha-synuclein and tau accumulation to Abeta deposition in the cerebral cortex of dementia with Lewy bodies.Exp Neurol. 2008 Apr;210(2):409-20. doi: 10.1016/j.expneurol.2007.11.019. Epub 2007 Dec 3. Exp Neurol. 2008. PMID: 18164295
-
Alpha-synuclein, Abeta and Alzheimer's disease.Prog Neuropsychopharmacol Biol Psychiatry. 2003 Feb;27(1):103-8. doi: 10.1016/S0278-5846(02)00339-1. Prog Neuropsychopharmacol Biol Psychiatry. 2003. PMID: 12551731 Review.
-
Parkinson's disease with dementia, lewy-body disorders and alpha-synuclein: recent advances and a case report.Acta Neurol Taiwan. 2011 Mar;20(1):4-14. Acta Neurol Taiwan. 2011. PMID: 21560084 Review.
Cited by
-
Dihydromyricetin and Salvianolic acid B inhibit alpha-synuclein aggregation and enhance chaperone-mediated autophagy.Transl Neurodegener. 2019 Jun 15;8:18. doi: 10.1186/s40035-019-0159-7. eCollection 2019. Transl Neurodegener. 2019. PMID: 31223479 Free PMC article.
-
CK1BP Reduces α-Synuclein Oligomerization and Aggregation Independent of Serine 129 Phosphorylation.Cells. 2021 Oct 21;10(11):2830. doi: 10.3390/cells10112830. Cells. 2021. PMID: 34831053 Free PMC article.
-
α-Synuclein-mediated neurodegeneration in Dementia with Lewy bodies: the pathobiology of a paradox.Cell Biosci. 2021 Nov 19;11(1):196. doi: 10.1186/s13578-021-00709-y. Cell Biosci. 2021. PMID: 34798911 Free PMC article. Review.
-
Expanding role of molecular chaperones in regulating α-synuclein misfolding; implications in Parkinson's disease.Cell Mol Life Sci. 2017 Feb;74(4):617-629. doi: 10.1007/s00018-016-2340-9. Epub 2016 Aug 13. Cell Mol Life Sci. 2017. PMID: 27522545 Free PMC article. Review.
-
Exogenous α-synuclein hinders synaptic communication in cultured cortical primary rat neurons.PLoS One. 2018 Mar 22;13(3):e0193763. doi: 10.1371/journal.pone.0193763. eCollection 2018. PLoS One. 2018. PMID: 29565978 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
